The authors' objective appears to be to review and summarise the published evidence comparing the incidence of acute and chronic graft-versus-host disease (GVHD) and malignant relapse following peripheral blood stem cell transplantation (PBSCT), with that following bone marrow transplantation (BMT).
relapse rates.
The extracted data were collected by one author, who also reviewed the manuscripts when discrepancies in the data extraction arose. An attempt was made to contact all primary authors for missing or incomplete information.
Methods of synthesis
How were the studies combined? The data were combined by a meta-analysis, which used both a fixed-effect model and the random-effects model of DerSimonian and Laird (see Other Publications of related Interest no.1) to obtain a pooled effect estimate of the relative risks (RRs) for acute and chronic GVHD, along with 95% confidence intervals (CIs).
Meta-regression analyses were used to either explore heterogeneity in the included studies or to test a clinical hypothesis. A meta-regression model with two covariates (stem cell source and the difference of the T-cell doses delivered) was developed to explore the differences between the PBSCT and BMT groups.
Adjusted rank correlation tests and asymmetry tests (see Other Publications of Related Interest nos.2-3) were used to assess any impact of publication bias on the reported outcomes. In addition, graphical funnel plots were generated to enable a visual inspection for publication bias.
How were differences between studies investigated?
Inter-study heterogeneity was assessed using the Q statistic and by the subsequent generation of a Cochran chi-squared value. Where appropriate, sensitivity analyses were undertaken to explore significant inter-study heterogeneity.
Results of the review
A total of 16 studies with 2,144 participants were included in the meta-analysis: 4 randomised trials (n=660), 1 nonrandomised trial (n=39), 6 cohort studies (n=289) using historical controls, and 5 retrospective cohort studies (n=1,156). The numbers of participants in each of the PBSCT and BMT groups were not reported.
Fifteen studies, including 5 randomised trials and 10 cohort studies, reported the incidence of acute GVHD. There was an increased risk of acute GVHD, after PBSCT compared with BMT; the RR using the random-effects model was 1.16 (95% CI: 1.04, 1.28, p=0.006). This estimate was equivalent to that obtained using the fixed-effect model, because of extremely low heterogeneity between the studies (Q=8.65, d.f.=14, p=0.85). Restricting the analysis to randomised trials did not affect this result. Data regarding the severity of GVHD was available for 10 studies. This showed no significant difference between the two graft types; the RR for severe acute GVHD (grade 3 to 4) after PBSCT, compared with BMT, was 0.99 (95% CI: 0.79, 1.24).
Fourteen studies, including 5 randomised trials and 9 cohort studies, reported the incidence of chronic GVHD. There was an increased risk of chronic GVHD after PBSCT, compared with BMT; the RR using the random-effects model was 1.53 (95% CI: 1.25, 1.88, p<0.001). This estimate had a moderate amount of heterogeneity (Q=42.38, d.f.=13, p<0.001). Restricting the analysis to randomised trials did not affect this result. Twelve studies reported the incidence of clinically extended versus limited chronic GVHD. There was an increased risk of clinically extensive chronic GVHD after PBSCT, compared with BMT; the RR using the random-effects model was 1.66 (95% CI: 1.35, 2.05, p<0.001). Data from one large, retrospective database review were excluded from this analysis.
